News coverage about Johnson & Johnson (NYSE:JNJ) has trended positive on Friday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Johnson & Johnson earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.6840863155069 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Johnson & Johnson (NYSE:JNJ) traded up $0.65 on Friday, reaching $139.98. The company had a trading volume of 5,990,475 shares, compared to its average volume of 5,873,761. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The firm has a market cap of $376,060.00, a PE ratio of 19.61, a P/E/G ratio of 2.85 and a beta of 0.82.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same period last year, the firm earned $1.68 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. equities analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.40%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

JNJ has been the topic of a number of research reports. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Royal Bank Of Canada increased their price target on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Citigroup initiated coverage on Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and increased their price target for the stock from $125.00 to $130.00 in a research report on Wednesday, September 20th. Finally, Jefferies Group upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the stock from $145.00 to $157.00 in a research report on Wednesday, October 11th. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $144.59.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Earns Daily Coverage Optimism Score of 0.28” was posted by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/01/johnson-johnson-jnj-earns-daily-coverage-optimism-score-of-0-28.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Insider Buying and Selling by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.